申联生物(688098) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 was ¥119,387,375.73, representing a decrease of 19.08% compared to the same period last year[4]. - Net profit attributable to shareholders was ¥47,470,138.97, down 38.09% year-on-year[4]. - Basic earnings per share decreased by 42.11% to ¥0.11, primarily due to the decline in net profit[4]. - The company experienced a 9.84% decline in revenue for the year-to-date period, attributed to the relocation of the peptide vaccine production line[4]. - Total revenue for the first three quarters of 2021 was CNY 272,415,976.87, a decrease of 9.83% compared to CNY 302,156,760.61 in the same period of 2020[24]. - Net profit for the third quarter of 2021 was CNY 90,049,371.98, down 34.4% from CNY 137,427,634.06 in the same quarter of 2020[25]. - Total comprehensive income for the third quarter of 2021 was CNY 90,049,371.98, compared to CNY 137,427,634.06 in the same period of 2020, representing a decrease of approximately 34.5%[26]. - Basic earnings per share for Q3 2021 was CNY 0.22, down from CNY 0.34 in Q3 2020, reflecting a decline of about 35.3%[26]. Research and Development - Research and development expenses totaled ¥10,927,924.94, an increase of 57.65% compared to the same period last year, accounting for 9.15% of revenue[5]. - Research and development expenses totaled 75.79 million RMB, with increased capitalized R&D investments for new vaccines[9]. - The company plans to capitalize on the new veterinary drug registration certificate obtained for the swine circovirus type 2 subunit vaccine[8]. - The company is focused on expanding its market presence and enhancing its product offerings through new vaccine developments[9]. - The company’s two peptide vaccine products received approval for market sales in early September 2021[15]. Assets and Liabilities - Total assets increased by 6.51% to ¥1,613,017,261.81 compared to the end of the previous year[5]. - The company's total assets as of September 30, 2021, were CNY 1,613,017,261.81, an increase from CNY 1,514,469,447.73 at the end of 2020[21]. - Current assets totaled CNY 768,247,671.52, slightly down from CNY 793,859,102.41 at the end of 2020[19]. - Non-current assets increased to CNY 844,769,590.29 from CNY 720,610,345.32 at the end of 2020[19]. - The total liabilities increased to CNY 146,128,760.41 from CNY 118,203,564.13 at the end of 2020[20]. - The equity attributable to shareholders of the parent company reached CNY 1,468,877,302.00, up from CNY 1,396,412,887.45 at the end of 2020[21]. Cash Flow - Net cash flow from operating activities for the first nine months of 2021 was CNY 13,944,598.26, a significant improvement from a net outflow of CNY 5,398,127.50 in the same period of 2020[29]. - Cash inflow from operating activities totaled CNY 213,622,372.72 in Q3 2021, compared to CNY 146,441,506.58 in Q3 2020, indicating an increase of approximately 45.8%[29]. - Cash outflow from operating activities was CNY 199,677,774.46 in Q3 2021, compared to CNY 151,839,634.08 in Q3 2020, marking an increase of about 31.5%[29]. - The cash and cash equivalents balance at the end of Q3 2021 was CNY 82,949,840.46, down from CNY 134,758,718.48 at the end of Q3 2020, reflecting a decrease of approximately 38.5%[30]. - The company reported a total cash inflow from financing activities of CNY 8,566,589.30 in Q3 2021, compared to CNY 600,302.80 in Q3 2020, indicating a substantial increase[30]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,113[11]. - Major shareholder Yang Yufang holds 21.93% of the shares, while UNITED BIOMEDICAL, INC. holds 15.13%[11]. Management and Expenses - The increase in management expenses was mainly due to the rising costs associated with the foot-and-mouth disease inactivated vaccine[8]. - The company reported a total of ¥3,865,841.60 in non-recurring gains and losses for the current period[8]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, decreased by 32.44% year-on-year[9]. - Operating income declined due to a delay in production following the re-approval of the product in early September 2021[9]. - The company reported a total of 25,805,141.64 in employee compensation payable[34].